ABBV-706 + Atezolizumab for Small Cell Lung Cancer
(SEZanne Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores a new treatment for individuals with extensive-stage small cell lung cancer (SCLC), a fast-growing type of lung cancer. Researchers aim to determine if a new drug, ABBV-706, combined with atezolizumab (an immunotherapy drug), is safe and effective compared to usual treatment options. Participants will be divided into groups to receive different doses of ABBV-706 with atezolizumab or the standard care. Those diagnosed with extensive-stage SCLC who have not yet received treatment may be suitable for this study. As a Phase 2 trial, this study measures the treatment's effectiveness in an initial, smaller group, offering a chance to contribute to important research.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research shows that combining ABBV-706 and atezolizumab may help treat small cell lung cancer (SCLC). In earlier studies, most patients experienced side effects, which are common with cancer treatments. Specifically, about 94.9% of patients taking atezolizumab had side effects, compared to 92.3% with other treatments. This suggests the combination is generally well-tolerated, though side effects are common.
The combination of ABBV-706 and atezolizumab has also effectively reduced cancer cells in the blood. While promising, the treatment is still under investigation. The trial aims to determine the best dose and ensure the combination's safety for patients. Overall, the treatment shows potential, but like all trials, it involves risks and benefits that must be considered.12345Why are researchers excited about this trial's treatments?
Researchers are excited about ABBV-706 in combination with atezolizumab for small cell lung cancer because it introduces a novel approach compared to standard treatments like etoposide and carboplatin. ABBV-706 targets specific cancer cell markers, potentially offering a more precise attack on cancer cells while sparing healthy ones. This targeted mechanism could lead to better efficacy and fewer side effects than traditional chemotherapy options. Additionally, the combination with atezolizumab, an immunotherapy, may enhance the body's immune response against cancer, providing a powerful one-two punch against tumor growth.
What evidence suggests that this trial's treatments could be effective for small cell lung cancer?
Research has shown that using ABBV-706 with atezolizumab may help treat small cell lung cancer (SCLC). In studies, this combination caused tumors to shrink in 96.2% of patients evaluated. It also quickly reduced cancer-related DNA and cells in the blood, indicating strong efficacy against cancer. The period during which the cancer did not worsen was about 4.9 months, which is promising for SCLC. In this trial, participants will receive either ABBV-706 at varying doses combined with atezolizumab or a standard care regimen. These early results suggest that ABBV-706 with atezolizumab could effectively manage this aggressive cancer.12345
Who Is on the Research Team?
ABBVIE INC.
Principal Investigator
AbbVie
Are You a Good Fit for This Trial?
Adults with previously untreated extensive stage small cell lung cancer (ES-SCLC) who are in good physical condition (ECOG Performance Status of 0 to 1), have measurable disease, and have had a brain scan if metastases are suspected. It's not for those who don't meet these criteria.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Safety Lead-In
Participants receive intravenous ABBV-706 in 1 of 2 doses with atezolizumab, or SOC to assess safety and determine the optimal dose
Expansion
Participants receive intravenous ABBV-706 in 1 of 2 doses with atezolizumab, or SOC until the optimal dose is determined
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ABBV-706
- Atezolizumab
Trial Overview
The trial is testing the safety and effectiveness of ABBV-706 combined with atezolizumab versus standard chemotherapy treatments. Participants will be randomly assigned to receive one of two doses of ABBV-706 plus atezolizumab or standard care, including etoposide, carboplatin, and optional lurbinectedin.
How Is the Trial Designed?
6
Treatment groups
Experimental Treatment
Participants will receive SOC (etoposide, carboplatin, atezolizumab, and optional lurbinectedin), as part of the approximately 69.5 month study duration.
Participants will receive ABBV-706 dose B in combination with atezolizumab, as part of the approximately 69.5 month study duration.
Participants will receive ABBV-706 dose A in combination with atezolizumab, as part of the approximately 69.5 month study duration.
Participants will receive SOC (etoposide, carboplatin, atezolizumab, and optional lurbinectedin), as part of the approximately 69.5 month study duration.
Participants will receive ABBV-706 dose B in combination with atezolizumab, as part of the approximately 69.5 month study duration.
Participants will receive ABBV-706 dose A in combination with atezolizumab, as part of the approximately 69.5 month study duration.
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois
Citations
NCT07155174 | A Study to Evaluate the Optimal Dose ...
ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ...
Advances With Checkpoint Inhibitors, T-Cell Engagers, and ...
The median PFS was 4.9 months (95% CI, 4.2-5.5), with 3-, 6-, and 9-month PFS rates of 68.0% (95% CI, 59.4%-75.2%), 35.3% (95% CI, 27.3%-43.4%), ...
A Study to Evaluate the Optimal Dose, Adverse Events and ...
The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) ...
4.
news.abbvie.com
news.abbvie.com/2025-10-13-AbbVie-to-Present-New-Data-at-ESMO-2025-Reinforcing-Leadership-in-Advancing-Targeted-Therapies-for-Solid-TumorsAbbVie to Present New Data at ESMO 2025 Reinforcing ...
In the same trial, ABBV-706 treatment also resulted in rapid clearance of circulating tumor DNA (ctDNA) and circulating tumor cells (CTC).
Immunotherapy Instills Renewed Promise in SCLC
Data presented during this year's ASCO annual meeting showed tumor shrinkage occurring in 96.2% of patients ( 50 of 52) with evaluable targeted ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.